A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

Allogeneic hematopoietic cell transplantation (alloHCT) is an intensive and potentially curative therapy for patients with high-risk hematologic malignancies, bone marrow failure syndromes, and other non-malignant conditions. A common complication of alloHCT is graft-versus-host disease (GVHD), which can be a significant contributor to morbidity and mortality.1,2 Classic acute GVHD predominantly affects the skin, liver, and gastrointestinal tract. Traditional acute GVHD grading is based upon physician report, primarily consisting of measurements of percent body area of rash, presence of nausea and anorexia, and volume of diarrhea.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research